Knowledge is power.
The Kellis IP Weekly
Since living in Brazil from 2021-2024 as the USPTO’s Intellectual Property Attaché for Brazil, Argentina, Paraguay, Uruguay, Guyana, and Suriname, Mr. Kellis has published the Kellis IP Weekly to help interested parties stay informed regarding intellectual property developments in Brazil and the surrounding region. If you have questions or concerns about any of the developments described in the Kellis IP Weekly and how those developments might impact your business, please contact Kellis IP.
Search the Kellis IP Weekly
The Kellis IP Weekly: Issue 10.5
INPI Releases Study on Patenting Scenario Surrounding Monoclonal Antibodies for Breast Cancer Treatment: The study, coordinated by INPI and conducted by the Technical Group for Intelligence in Industrial Property under the Interministerial Group for Intellectual Property (GIPI), evaluates patent applications related to the monoclonal antibodies trastuzumab and pertuzumab (which are costly for Brazil’s universal health system, SUS, to acquire) . . .
Click below to read more and see additional headlines.
The Kellis IP Weekly: Issue 10.2
This week I had a conversation with an investor who routinely declines investment opportunities in Brazil—where he was born and raised—because “Brazil is not a serious country.” He ultimately explained that as an investor, he cannot count on Brazilian institutions to act in a predictable way, and as a result cannot justify the risk associated with investments in the country. This investor’s opinion is reflected in Brazil’s score on the . . .
Click below to read more and see additional headlines.
The Kellis IP Weekly: Issue 8.4
Patent Pendency, Regulatory Data Protection Discussed at Health Forum: The August 21st Health Forum, hosted by think tank Esfera Brasil and Brazilian pharmaceutical laboratory EMS, featured multiple high-level speakers and attendees, including . . .
Click below to see more headlines.